齐鲁制药：以“有温度的科技”锻造新质生产力

Core Viewpoint - Shandong Province has achieved a significant milestone by entering the 10 trillion yuan economy club, attracting national attention for its high-quality economic and social development [1] Group 1: Industry Development - The 20th National Congress of the Communist Party emphasized the implementation of a health-first development strategy, which provides fundamental guidance for the pharmaceutical industry [3] - Domestic pharmaceutical companies are seizing opportunities during a transformative period, focusing on innovation, internationalization, and green intelligence to create new development scenarios [3] - Qilu Pharmaceutical has made significant strides, with 143 new products developed and launched during the 14th Five-Year Plan, including 109 products winning national procurement bids and 38 being the first or only domestic listings [3][5] Group 2: Innovation and Product Development - Qilu Pharmaceutical's innovative drug, Ilruak (启欣可), has been approved for treating advanced non-small cell lung cancer, providing hope for patients [5][8] - The company has also developed a PD-1/CTLA-4 dual-function antibody, expected to offer a more effective and safer treatment for recurrent or metastatic cervical cancer [8] - Qilu's strategy balances innovation and generic drug development, addressing urgent clinical needs and enhancing drug accessibility [9] Group 3: International Expansion - Qilu Pharmaceutical has transitioned from a cost-driven model to a value-creating approach in international markets, becoming a notable player in the global pharmaceutical landscape [12] - The company responded to a clinical drug shortage in the U.S. by quickly facilitating the export of cisplatin injection, showcasing its capability and reliability in international supply [12] - Qilu's generic drug, gefitinib (伊瑞可), significantly reduced the price of a previously monopolized drug, enhancing accessibility for over 100,000 patients [13] Group 4: Manufacturing and Sustainability - Qilu Pharmaceutical has integrated smart manufacturing into its production processes, achieving high-quality and efficient drug production [16][17] - The company has invested nearly 2.1 billion yuan in environmental protection facilities and 2.7 billion yuan in safety and environmental expenditures during the 14th Five-Year Plan [20] - Qilu has received recognition for its green factories, with seven subsidiaries awarded national-level green factory status, reflecting its commitment to sustainable development [20] Group 5: Future Outlook - Qilu Pharmaceutical aims to become a world-class pharmaceutical enterprise, contributing to the "Healthy China" initiative and global health efforts [21]